vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Village Farms International, Inc. (VFF). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $12.2M, roughly 1.3× Village Farms International, Inc.). Village Farms International, Inc. runs the higher net margin — 19.9% vs -7.8%, a 27.6% gap on every dollar of revenue. On growth, Village Farms International, Inc. posted the faster year-over-year revenue change (31.5% vs 27.3%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.
DERM vs VFF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $12.2M |
| Net Profit | $-1.2M | $2.4M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | — |
| Net Margin | -7.8% | 19.9% |
| Revenue YoY | 27.3% | 31.5% |
| Net Profit YoY | -182.0% | 128.2% |
| EPS (diluted) | $-0.04 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $12.2M | ||
| Q3 25 | $17.0M | $66.7M | ||
| Q2 25 | $15.0M | $59.9M | ||
| Q1 25 | $13.1M | $77.1M | ||
| Q4 24 | $12.6M | — | ||
| Q3 24 | $14.6M | $54.9M | ||
| Q2 24 | $14.9M | $53.6M | ||
| Q1 24 | $13.0M | $78.1M |
| Q4 25 | $-1.2M | $2.4M | ||
| Q3 25 | $-2.3M | $10.2M | ||
| Q2 25 | $-3.8M | $26.5M | ||
| Q1 25 | $-4.1M | $-6.7M | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $-2.4M | $-820.0K | ||
| Q2 24 | $-3.4M | $-23.5M | ||
| Q1 24 | $-10.4M | $-2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 47.9% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 14.7% | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | 24.8% | ||
| Q2 24 | 56.0% | 25.4% | ||
| Q1 24 | 47.7% | 19.9% |
| Q4 25 | -2.8% | — | ||
| Q3 25 | -9.0% | 23.3% | ||
| Q2 25 | -19.2% | 20.8% | ||
| Q1 25 | -25.3% | -8.0% | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | -19.8% | 3.8% | ||
| Q2 24 | -19.7% | -43.5% | ||
| Q1 24 | -77.4% | -3.0% |
| Q4 25 | -7.8% | 19.9% | ||
| Q3 25 | -13.6% | 15.3% | ||
| Q2 25 | -25.3% | 44.2% | ||
| Q1 25 | -31.0% | -8.7% | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | -16.3% | -1.5% | ||
| Q2 24 | -22.6% | -43.9% | ||
| Q1 24 | -80.1% | -3.7% |
| Q4 25 | $-0.04 | $0.01 | ||
| Q3 25 | $-0.09 | $0.08 | ||
| Q2 25 | $-0.16 | $0.24 | ||
| Q1 25 | $-0.18 | $-0.06 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $-0.12 | $-0.01 | ||
| Q2 24 | $-0.17 | $-0.21 | ||
| Q1 24 | $-0.53 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $81.2M |
| Total DebtLower is stronger | $25.3M | $33.7M |
| Stockholders' EquityBook value | $31.9M | $299.9M |
| Total Assets | $94.6M | $423.1M |
| Debt / EquityLower = less leverage | 0.79× | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $81.2M | ||
| Q3 25 | $24.9M | $82.6M | ||
| Q2 25 | $20.3M | $60.0M | ||
| Q1 25 | $21.1M | $15.1M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $22.5M | $28.7M | ||
| Q2 24 | $23.9M | $29.7M | ||
| Q1 24 | $24.1M | $26.7M |
| Q4 25 | $25.3M | $33.7M | ||
| Q3 25 | $25.2M | $34.6M | ||
| Q2 25 | $25.1M | $39.1M | ||
| Q1 25 | $25.0M | $39.2M | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | $43.3M | ||
| Q2 24 | $19.7M | $44.4M | ||
| Q1 24 | $14.7M | $46.1M |
| Q4 25 | $31.9M | $299.9M | ||
| Q3 25 | $25.9M | $295.4M | ||
| Q2 25 | $19.2M | $284.3M | ||
| Q1 25 | $21.5M | $248.3M | ||
| Q4 24 | $20.1M | — | ||
| Q3 24 | $10.9M | $274.4M | ||
| Q2 24 | $11.3M | $275.2M | ||
| Q1 24 | $13.0M | $296.2M |
| Q4 25 | $94.6M | $423.1M | ||
| Q3 25 | $85.2M | $418.4M | ||
| Q2 25 | $81.2M | $403.7M | ||
| Q1 25 | $85.0M | $377.1M | ||
| Q4 24 | $80.2M | — | ||
| Q3 24 | $64.0M | $417.8M | ||
| Q2 24 | $65.2M | $425.4M | ||
| Q1 24 | $66.6M | $458.4M |
| Q4 25 | 0.79× | 0.11× | ||
| Q3 25 | 0.97× | 0.12× | ||
| Q2 25 | 1.30× | 0.14× | ||
| Q1 25 | 1.16× | 0.16× | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | 0.16× | ||
| Q2 24 | 1.75× | 0.16× | ||
| Q1 24 | 1.13× | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 90.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | — | ||
| Q3 25 | $-2.4M | $24.4M | ||
| Q2 25 | $-942.0K | — | ||
| Q1 25 | $-2.8M | $-6.4M | ||
| Q4 24 | $2.2M | — | ||
| Q3 24 | $-1.2M | $4.3M | ||
| Q2 24 | $-5.2M | $5.7M | ||
| Q1 24 | $-5.0M | $-50.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $22.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-8.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $4.8M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 33.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -11.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 9.0% | ||
| Q1 24 | — | -2.5% |
| Q4 25 | — | 90.8% | ||
| Q3 25 | — | 2.7% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | 1.6% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
VFF
| International Sales | $8.7M | 71% |
| Cannabis United States Segment | $3.4M | 27% |
